Abstract
Increased abundance of βII- and βIII-tubulin isotypes in cancer cells confers resistance to vinca and taxoid site drugs; however, the role of these isotypes in the acquired resistance of cancer cells to non-vinca or non-taxoid site binding agents has not been described. Peloruside A (PLA) and laulimalide are the only known non-taxoid site microtubule-stabilizing agents. A human ovarian cancer cell line, 1A9-L4 (L4), previously selected in high concentrations of laulimalide, has both a single point mutation in βI-tubulin and overexpression of βII- and βIII-tubulin. The cells are highly resistant to PLA as well as laulimalide but show no cross-resistance to taxoid site drugs or drugs that bind to the vinca site on β-tubulin. To understand the functional significance of the βII- and βIII-tubulin changes in this resistant cell line, isotype-specific short interfering RNA was used to knock down the expression of the βII and βIII isotypes, and the cellular effects of PLA and laulimalide were examined before and after silencing. It was found that inhibition of βII- and βIII-tubulin partially sensitized L4 cells to PLA and laulimalide, as seen by increased potency of PLA and laulimalide for inducing growth inhibition, cellular tubulin polymerization, microtubule aberrations, and G(2)-M arrest in the resistant cells. The sensitivity to paclitaxel, vinblastine, ixabepilone, and cisplatin was unaffected by the inhibition of isotype expression. It was concluded that the increased βII- and βIII-tubulin contributed significantly to the resistance phenotype, along with the tubulin structural mutation, and that the altered isotype effect was binding site specific.
Highlights
The resistance of cancer cells to antimicrotubule agents is a serious clinical problem in the successful treatment of cancer
We recently showed that selection of a human ovarian carcinoma cell line, 1A9-L4 (L4), in the presence of high concentrations of laulimalide led to multiple b-tubulin alterations that included a bI-tubulin structural mutation R306H/C, in addition to increased abundance of bII- and bIII-tubulin isotypes [22]
To determine the role of bII- and bIII-tubulin isotypes in the chemoresistance to Peloruside A (PLA) and laulimalide, isotypespecific short interfering RNA (siRNA) were used to silence the expression of bII- and/or bIII-tubulin in L4 cells
Summary
The resistance of cancer cells to antimicrotubule agents is a serious clinical problem in the successful treatment of cancer. There are only a limited number of studies that have directly investigated the functional significance of these isotypes in antimitotic drug resistance Some of these studies used cell lines that were selected with taxoid or vinca site drugs or that naturally overexpressed bII- or bIII-tubulin. Understanding the role of bII- and bIII-tubulin in the resistance to a different class of tubulin-binding agents would help to further clarify the complex mechanisms of action of the b-tubulin isotypes in www.aacrjournals.org contributing to survival of cancer cells in the presence of diverse chemotherapeutic agents
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
